<div id="readability-page-1"><div><p><span>Anzalone Christopher Richard Chairman of the Board of Arrowhead Pharmaceuticals Inc [ARWR] filed a Form 4 on December 16, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:</span></p><div><table><tbody><tr><td><span>Date</span></td><td><span>12/15/25-12/16/25</span></td></tr><tr><td><span>Transaction</span></td><td><span>Surrender(1)</span></td></tr><tr><td><span>Shares</span></td><td><span>184,298</span></td></tr><tr><td><span>Price</span></td><td><span>$67.00</span></td></tr><tr><td><span>Value</span></td><td><span>$12,348,814</span></td></tr></tbody></table></div><p><span>Ending Holdings: 3,916,957 - Direct</span></p><ul><li><span>(1)</span></li><li><span>Surrender of shares back to company to pay option exercise cost and/or resulting tax liability.</span></li></ul><p><span>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.</span></p><p><span>Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.</span></p><span> </span></div></div>

ARWR

<p>Chairman Christopher Richard Anzalone of Arrowhead Pharmaceuticals Inc [ARWR] surrendered 184,298 shares at $67.00 each, valued at $12,348,814, to pay for option exercise costs and/or tax liabilities. His ending holdings are 3,916,957 shares. This was disclosed in a Form 4 filed with the SEC on December 16, 2025.</p>

Chmn Anzalone Surrenders 184,298 Of Arrowhead Pharmaceuticals Inc [ARWR]